Aki Nishioka

Aki Nishioka

Auto-generated profile, based on publicly available information

Aki Nishioka

Division of Diabetes, Endocrinology and Clinical Immunology, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 February 2019 in Modern Rheumatology
Verified
Journal Article
Closed access
ANAki Nishioka
Aki Nishioka
STShinichiro Tsunoda
Shinichiro Tsunoda
TATakeo Abe
Takeo Abe
TYTakahiro Yoshikawa
Takahiro Yoshikawa
MTMiki Takata
Miki Takata
HSHajime Sano
Hajime Sano
Objective: This study identified biomarkers that can be used to assess disease activity and response to therapy in patients with interstitial lung disease complicating anti-melanoma differentiation-associated gene 5 (MDA5) antibody (Ab)-positive clinically amyopathic dermatomyositis (CADM). Methods: In 15 patients with interstitial lung disease complicating anti-MDA5 Ab-positive CADM, anti-MDA5 Ab, neopterin, interleukin (IL)-18, ferritin, and soluble interleukin 2 receptor (sIL-2R) levels were measured in cryopreserved serum specimens before and at multiple times after remission induction therapy, and their correlations were assessed. Results: Anti-MDA5 Ab, neopterin, IL-18, ferritin, and sIL-2R levels did not differ significantly between patients who survived and those who succumbed to the disease. In many cases, serum anti-MDA5 Ab titers were over the upper limit (over 150 index value) before treatment in the usual measuring method, and gradually decreased to the normal range at stable phase. Meanwhile, serum neopterin levels (21.6 [15.3-48.3] nmol/L) were significantly elevated in newly diagnosed patients and fell to 6.8 (5-11.4) nmol/L at 6 months after treatment introduction. Conclusions: Elevated serum neopterin as well as ferritin, sIL-2R, KL-6, and anti-MDA5 Ab titer might help identify patients with interstitial lung disease complicated with DM and might be useful in monitoring response to therapy.

30 July 2020 in Modern Rheumatology
Verified
Journal Article
Closed access
NANaoto Azuma
Naoto Azuma
YKYoshinori Katada
Yoshinori Katada
TYTakahiro Yoshikawa
Takahiro Yoshikawa
YYYuichi Yokoyama
Yuichi Yokoyama
ANAki Nishioka
Aki Nishioka
KMKiyoshi Matsui
Kiyoshi Matsui
Objectives: To assess oral health-related quality of life (OHRQoL) and changes in OHRQoL in three years of patients with Sjögren’s symdrome (SS). Methods: Thirty-five SS patients and 23 non-SS individuals were enrolled. OHRQoL were quantitatively evaluated using the shortened Oral Health Impact Profile (OHIP-14). After three years, 22 patients and 14 controls tool the OHIP-14 survey again. Results: The SS group had a significantly higher OHIP-14 score, which indicated a lower OHRQoL, than the non-SS group. Among individual questions in the OHIP-14, scores for “trouble pronouncing words”, “uncomfortable to eat foods”, “self-conscious”, and “diet unsatisfactory” were markedly higher in the SS group than in the non-SS group. The OHIP-14 score significantly increased in three years in the SS group. Furthermore, there was an inverse correlation between the change rate of salivary flow rate and change of OHIP-14 scores in three years in patients with SS whose OHIP-14 score increased. Scores for “irritable with other people”, “difficulty doing usual jobs”, “felt life less satisfying”, and “unable to function” significantly increased in three years. Conclusions: In SS, OHRQoL decreased in three years, which was associated with a decrease in saliva secretion. Moreover, troubles related to psychosocial aspects in SS patients were found to intensify over time.